What is Helocyte?
Founded by Fortress Biotech, Inc., Helocyte operates at the intersection of advanced immunology and clinical medicine. The company specializes in the development of innovative therapeutic agents designed to prevent and treat high-burden diseases. By focusing on the underlying mechanisms of viral infections and oncological progression, Helocyte provides healthcare providers and institutions with novel tools to improve patient outcomes. Its market position is defined by a rigorous approach to clinical-stage development, ensuring that its therapeutic candidates meet the stringent requirements of modern medical practice while addressing significant gaps in current treatment paradigms.
How much funding has Helocyte raised?
Helocyte has raised a total of $7M across 2 funding rounds:
Debt
$3M
Debt
$4M
Debt (2016): $3M, investors not publicly disclosed
Debt (2016): $4M, investors not publicly disclosed
Key Investors in Helocyte
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Helocyte?
With the recent infusion of capital, Helocyte is poised to transition its lead candidates through critical clinical trial phases. The strategic roadmap emphasizes the expansion of its immunotherapy portfolio, with a specific focus on scaling research operations to meet the demands of global healthcare markets. As the company continues to refine its clinical development strategy, the focus will remain on achieving regulatory milestones and establishing long-term efficacy for its pipeline. This phase of growth is essential for Helocyte to solidify its reputation as a leader in the development of next-generation treatments for infectious diseases and cancer, ultimately driving value for stakeholders and patients alike.
See full Helocyte company page
